These findings implicate PTPRH as a potent modulator of glycolysis and tumor aggressiveness via PI3K/AKT/mTOR activation, reinforcing its value as a therapeutic target in NSCLC. The gene discussed is PIK3CD; the disease is non-small cell lung carcinoma.